Companies › SPH-BIOCAD (HK)
1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BCD-261 anti-TL1A human monoclonal antibody | TL1A | Phase 1 | Healthy Adult Participants | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07535775 | BCD-261 | Phase 1 | Healthy Adult Participants | Other | Mar 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.